Who published this market news?

TradingView published this market news item.

Bluejay Diagnostics completes enrollment of 750 patients in pivotal SYMON-II sepsis study

Bluejay Diagnostics announced completion of enrollment of 750 patients in its SYMON-II pivotal study, achieved ahead of plan.Key Highlights:Original SEC Filing: Bluejay Diagnostics, Inc. [ BJDX ] - 8-K - Jul. 22, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying imp…

Bluejay Diagnostics announced completion of enrollment of 750 patients in its SYMON-II pivotal study, achieved ahead of plan.

Key Highlights:

SYMON-II reached targeted enrollment of 750 patients earlier than anticipated, marking a key operational milestone.
The study evaluates Symphony IL-6 for early assessment of 28-day all-cause mortality risk in ICU-intended sepsis patients.
Preliminary enrolled population shows ~17% 28-day mortality, providing a robust dataset to assess IL-6 prognostic utility.
Company expects data cleaning, statistical analysis, and clinical reporting in coming months to support regulatory strategy.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.